Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies…

By Dr. Matthew Watson

COPENHAGEN, Denmark, April 17, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

Read the rest here:
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...

Related Post

• Telesis Bio Announces Reverse Stock Split - May 7th, 2024
• Shockwave Medical Reports First Quarter 2024 Financial Results - May 7th, 2024
• Aileron Therapeutics to Present at Two Upcoming Investor Conferences - May 7th, 2024
• ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates - May 7th, 2024
• Sana Biotechnology to Present at May and June 2024 Investor Conferences - May 7th, 2024
• Day One Reports First Quarter 2024 Financial Results and Corporate Progress - May 7th, 2024
• Immuneering Recognizes Melanoma Awareness Month - May 7th, 2024
• T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity - May 7th, 2024
• Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024 - May 7th, 2024
• T2 Biosystems Announces Commercial Expansion Through Middle East Distributor - May 7th, 2024
• Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 - May 7th, 2024
• BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million - May 7th, 2024
• Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2024
• T2 Biosystems Announces First Quarter 2024 Financial Results - May 7th, 2024
• argenx to Present at BofA Securities 2024 Health Care Conference - May 7th, 2024
• Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update - May 7th, 2024
• Sandoz reports first quarter 2024 sales - May 7th, 2024
• Memo Therapeutics increases Series C financing to CHF 45 million - May 7th, 2024
• Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 - May 7th, 2024
• Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 7th, 2024
• Medigene AG reports Financial Results and Business Update for Q1 2024 - April 28th, 2024
• Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
• Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
• Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
• Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
• Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
• Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
• Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
• Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
• HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
• Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
• Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
• Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
• UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
• CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
• BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
• Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
• Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
• Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
• Financière de Tubize - Dividend approval - April 28th, 2024
• Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant... - April 19th, 2024
• Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces... - April 19th, 2024
• Sanara MedTech Inc. Announces $55 Million Debt Facility - April 19th, 2024
• Pharming Group announces the placement of €100 million convertible bonds due 2029 - April 19th, 2024
• Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation - April 19th, 2024
• Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00 - April 19th, 2024
• Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States - April 19th, 2024
• Immix Biopharma on Track to Dose NXC-201 Patients in United States - April 19th, 2024
• Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - April 19th, 2024
• PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine - April 19th, 2024
• ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET - April 19th, 2024
• NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s &... - April 19th, 2024
• Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - April 19th, 2024
• Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted... - April 19th, 2024
• Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - April 19th, 2024
• Codexis to Report First Quarter 2024 Financial Results on May 2 - April 19th, 2024
• Addex to Present at the Swiss Biotech Day 2024 - April 19th, 2024
• Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - April 19th, 2024
• Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - April 19th, 2024
• FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer - April 19th, 2024
• Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B... - April 10th, 2024
• Ultimovacs – Invitation to Business Update on April 17, 2024 - April 10th, 2024
• Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective... - April 10th, 2024
• Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - April 10th, 2024
• Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 - April 10th, 2024
• Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today - April 10th, 2024
• ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 - April 10th, 2024
• Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - April 10th, 2024
• SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious... - April 10th, 2024
• Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results - April 10th, 2024
• Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference - April 10th, 2024
• Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2... - April 10th, 2024
• Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting - April 10th, 2024
• IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 - April 10th, 2024
• Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300... - April 10th, 2024
• Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual... - April 10th, 2024
• Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting - April 10th, 2024
• Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 - April 10th, 2024
• ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients... - April 10th, 2024
• Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024 - April 10th, 2024

Global News Feed Comments Off on Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies… | April 19th, 2021

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,969)
• Cardiac Stem Cells (1,251)
• Global News Feed (2,935)
• Integrative Medicine (105)
• IPS Cell Therapy (458)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,181)
• Spinal Cord Stem Cells (954)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy